Early Alzheimer’s patients continue to benefit from 4 yrs of LEQEMBI(R) (lecanemab-irmb) Therapy, new clinical data presented at AAIC Read more
Pathways involved in DNA repair and other cellular functions could contribute to the development of Alzheimer’s, reveals MIT study Read more
Roche’s Brainshuttle technology promises next generation of amyloid beta mAbs, says GlobalData Read more
CNS market to surpass $80 bn in 2025, driven by MS and psychiatric drug innovation: GlobalData Read more
NICE rejects second Alzheimer’s drug but opportunity remains for decision change: GlobalData Read more
PharmaKure’s novel blood test can identify biomarkers in patients with Alzheimer’s Disease: Study Read more